In terms of combination of immunotherapy, the CD47 antibody that focuses on re‐education of TA‐MG and TA‐MAC needs to be combined with other immunotherapy such as dendritic vaccines and adoptive T‐cell therapy to treat gliomas. This evidence concerns the gene CD47 and glioma.